文章预览
专栏 活动 快讯 产品 解读 Xiangxiang Ma丨Anjie Broad Law Firm I. Introduction and Background On June 18, 2024, the National Medical Products Administration of People’s Republic of China issued the List of Typical Application Scenarios of Artificial Intelligence for Drug Governance (the “ List ”), presenting fifteen application scenarios that can play a leading demonstration role, possess characteristic of development potential, address pain points during the work, and tailor to more urgent needs. It is noted from the beginning of the List that, the following guiding regulations adopted previously are playing a fundamental role in framing the List: It is widely and notably recognized that application scenarios are pivotal when considering artificial intelligence (“ AI ”) empowering and supporting a variety of industrial sectors. According to the above-listed guided opinions and plans, issuance of a list describing various application scenarios have been underscore
………………………………
